Ignite Creation Date:
2025-12-25 @ 3:53 AM
Ignite Modification Date:
2025-12-26 @ 2:43 AM
Study NCT ID:
NCT00423202
Status:
COMPLETED
Last Update Posted:
2009-04-16
First Post:
2007-01-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2003-12
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2005-10
Completion Date Type:
None
First Submit Date:
2007-01-17
First Submit QC Date:
None
Study First Post Date:
2007-01-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2009-04-15
Last Update Post Date:
2009-04-16
Last Update Post Date Type:
ESTIMATED